OncoPharm Mirvetuximab Soravtansine
Nov 17, 2022
Discover a groundbreaking antibody-drug conjugate now approved for ovarian cancer! Dive into how mirvetuximab soravtansine targets folate receptor alpha, delivering a powerful DM4 microtubule inhibitor. Learn about practical prescribing, infusion procedures, and the management of potential eye toxicity. The podcast also highlights response rates from trials and discusses the implications of negative phase 3 results. Get insights on patient selection and where this innovative therapy fits in the treatment landscape.
AI Snips
Chapters
Transcript
Episode notes
Mechanism And Target Expression
- Mervituximab-seravtansine is a folate receptor alpha–directed antibody–drug conjugate delivering a DM4 microtubule inhibitor inside tumor cells.
- The antibody targets FRα which is overexpressed in ovarian, endometrial, TNBC, and some NSCLC tumors.
Calculate Dose Using Adjusted Body Weight
- Use adjusted ideal body weight (40% correction) to calculate the dosing for mervituximab-seravtansine.
- Pre-medicate with corticosteroid, antihistamine, antipyretic, and antiemetic and consider day-before meds for prior infusion reactions.
Prevent And Monitor Eye Toxicity
- Require baseline and periodic ophthalmology exams and prescribe topical steroid drops starting day −1 through day 4 around each dose.
- Instruct patients to avoid contacts, use lubricating drops, warm compresses, and sunglasses to reduce ocular toxicity.